NMS Pharmaceuticals Lists $1.9-Million Loss
NMS Pharmaceuticals Inc. said it lost $1.9 million for its fiscal 1986, ended May 31. The fiscal 1986 loss compares to a net loss of $1.4 million for the prior year. The Newport Beach maker of medical test kits said revenues fell 8% to $2.3 million from $2.5 million.
Company officials said they do not report fourth-quarter results, but controller Janet Moore agreed that, based on a previously reported nine-month net loss of $714,510, NMS lost $1.2 million during its fiscal fourth quarter. That loss would compare to a fiscal 1985 fourth-quarter loss of about $997,000.
Revenues during the fiscal 1986 fourth quarter were about $371,000, up 10% from $336,000 a year earlier.
According to the annual report NMS filed with the Securities and Exchange Commission last month, the fourth-quarter loss included $474,000 set aside as a provision against damages in a 18-month-old lawsuit. The suit was filed in U.S. District Court in Los Angeles by Helena Laboratories, a Texas-based competitor alleging that NMS unfairly obtained and used Helena’s trade secrets in the development of the NMS EZ Detect test for detecting blood in the stool.
Additionally, NMS incurred $236,100 in write-downs during the final quarter. The annual report said the write-downs were related to product lines NMS may discontinue, including the EZ Detect test kit--which would be dropped if Helena wins a court order to prohibit NMS from marketing the kits.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.